Drug Profile
Research programme: ophthalmic disease therapeutics controlled-release - AbbVie/InnoCore
Alternative Names: Intra-ocular implant - InnoCore; Intra-ocular microspheres - InnoCore; Sustained release ophthalmic disease therapeutics - Allergan/InnoCoreLatest Information Update: 18 May 2020
Price :
$50
*
At a glance
- Originator Allergan
- Developer AbbVie; InnoCore Pharmaceuticals
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Eye disorders
Most Recent Events
- 08 May 2020 Allergan has been acquired and merged into AbbVie
- 28 Jul 2018 No recent reports of development identified for preclinical development in Eye-disorders in Netherlands (Ophthalmic, Controlled release)
- 22 Oct 2013 Preclinical trials in Eye disorders in Netherlands (Ophthalmic, controlled release)